Sinovac Biotech, Ltd.
SVA
Get informed when a big investor buys or sells
+ FollowMarket Cap$464.94M
Close$
$15.63
141.6% upside
Current Fair Value
141.6% upsideUndervalued by 141.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $464.94 Million |
|---|---|
| Enterprise Value | $530.28 Million |
| Dividend Yield | $110.00 (-) |
| Earnings per Share | $-0.83 |
| Beta | 0 |
| Outstanding Shares | 99,603,965 |
Return
| Return on Equity | 0.31% |
|---|---|
| Return on Assets | 0.16% |
| Return on Invested Capital | -14.50% |
Valuation & Multiples
| P/E Ratio | -7.8 |
|---|---|
| PEG | 11.38 |
| Price to Sales | 0.34 |
| Price to Book Ratio | 0.1 |
| Enterprise Value to Revenue | 0.27 |
| Enterprise Value to EBIT | -0.52 |
| Enterprise Value to Net Income | 38 |
| Total Debt to Enterprise | 1.04 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
December 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sinovac Biotech, Ltd.
CEO: Weidong Yin